Stress and Neurofeedback in Anorexia Nervosa

Sponsor
University of California, San Diego (Other)
Overall Status
Recruiting
CT.gov ID
NCT05834816
Collaborator
(none)
300
1
1
71.2
4.2

Study Details

Study Description

Brief Summary

Anorexia nervosa (AN) and atypical AN (AAN) are severe psychiatric illnesses associated with high disease burden including high treatment costs and excessive mortality rates. Primary characteristics of AN and AAN are food restriction, associated fear of weight gain, and a disturbance in how one's body weight or shape is experienced.The underlying neural mechanisms for the core illness behaviors of food restriction and body size overestimation in anorexia nervosa and atypical anorexia nervosa are not well understood.

This project will use neurofeedback and advanced psychophysical methods to assess and moderate the neural and behavioral responses to stress and relate those results to the naturalistic environment. The results will guide the development of novel interventions.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Negative Affect Task
N/A

Detailed Description

The overall strategy is a cross-sectional study, involving 3 subject groups, each subject studied on two study days (one negative and one neutral affect day, randomized), one week apart; on both study days subjects will undergo functional magnetic resonance imaging (fMRI) during which they complete tasks for 1) neurofeedback-reward learning and 2) body size estimation. Before and after each scan, and in the week between scans, subjects will be assessed for positive and negative affect and how it affects food intake.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single Group AssignmentSingle Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Neural Mechanisms of Negative Affect and Neurofeedback in Anorexia Nervosa
Actual Study Start Date :
Apr 26, 2023
Anticipated Primary Completion Date :
Mar 31, 2029
Anticipated Study Completion Date :
Mar 31, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: Behavioral

Negative Affect Task

Behavioral: Negative Affect Task
fMRI stress task
Other Names:
  • Functional Magnetic Resonance Brain Imaging Stress Task
  • Outcome Measures

    Primary Outcome Measures

    1. Functional Magnetic Resonance Imaging (fMRI) brain activation in response to stress during a taste reward task [Difference in brain response between the neutral and stress condition, up to 9 days]

      Activation in the brain during a taste reward task will be measured using functional MRI (fMRI) after a neutral and stressful task.

    2. Functional Magnetic Resonance Imaging (fMRI) brain activation in response to stress during a body size estimation task [Difference in brain response between the neutral and stress condition, up to 9 days]

      Activation in the brain during a body size estimation task will be measured using functional MRI (fMRI) after a neutral and stressful task.

    Secondary Outcome Measures

    1. Ecological Momentary Assessment (EMA) [Up to 9 days]

      Ecological Momentary Assessment (EMA) will be used to test food restriction and body size estimation in the natural environment and in relation to daily stress.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Healthy Controls (HC)

    • Individuals aged 18-45 years

    • Healthy body weight between 90 and 110 % average body weight since puberty.

    • Regular monthly menstrual cycle (if applicable)

    • Edinburgh Handedness Inventory Revised (EHI-R) LQ* score > +200

    • All ethnic backgrounds

    • English is primary language spoken

    Anorexia Nervosa (AN)

    • Age 18-45 years old

    • Edinburgh Handedness Inventory Revised (EHI-R) LQ* score > +200

    • All ethnic backgrounds

    • Current diagnosis of anorexia nervosa, including being underweight, will have a severe fear of weight gain, body image distortion and absence of the menstrual cycle over three consecutive months.

    • English is primary language spoken

    Atypical Anorexia Nervosa (AAN)

    • Age 18-45 years old

    • Edinburgh Handedness Inventory Revised (EHI-R) LQ* score > +200

    • All ethnic backgrounds

    • Meets the criteria for anorexia nervosa except despite significant weight loss, the individual's weight is within or above the normal range

    • English is primary language spoken

    Exclusion Criteria:

    Healthy Controls (HC)

    • Current pregnancy or breast feeding within last 3 months

    • First degree relative with current or past eating disorder

    • Psychiatric Medication use such as selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, etc.

    • Past or present Axis I psychiatric disorder including substance or alcohol use disorder as determined through structured clinical interview

    • History of significant head trauma

    • Indication of intellectual disability or autism spectrum disorder

    • Major Medical illness that requires medication or have significant impact on subject's life such as: diabetes, Alzheimer's disease or dementia, stroke, learning disability, mobility disorders, cancer, high blood pressure, etc. (to be determined through biological screening form and interview with principal investigator (PI)

    • Recent history of suspected substance abuse or a lifetime history of psychostimulant abuse and/or dependence

    • Contraindications to magnetic resonance imaging (MRI) including metal implants or braces (as determined through fMRI screening form)

    Anorexia Nervosa (AN)

    • Pregnancy or breast feeding within last 3 months

    • Lifetime history of bipolar I disorder or psychosis

    • Current substance abuse or dependence in the past 3 months

    • Psychotic illness/other organic brain syndromes, dementia, somatization disorders or conversion disorders

    • Physical conditions (e.g., diabetes mellitus, pregnancy) known to influence eating or weight

    • History of significant head trauma

    • Indication of intellectual disability or autism spectrum disorder

    • Electrolyte, blood count or kidney or liver function abnormalities

    • Contraindications to MRI including metal implants or braces (as determined through fMRI screening form)

    Atypical Anorexia Nervosa (AAN)

    • Pregnancy or breast feeding within last 3 months

    • Lifetime history of bipolar disorder or psychosis

    • Current substance abuse or dependence in the past 3 months

    • Psychotic illness/other organic brain syndromes, dementia, somatization disorders or conversion disorders

    • Physical conditions (e.g., diabetes mellitus, pregnancy) known to influence eating or weight

    • History of significant head trauma

    • Indication of intellectual disability or autism spectrum disorder

    • Electrolyte, blood count or kidney or liver function abnormalities

    • Contraindications to MRI including metal implants or braces (as determined through fMRI screening form)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California San Diego San Diego California United States 92121

    Sponsors and Collaborators

    • University of California, San Diego

    Investigators

    • Principal Investigator: Guido Frank, MD, University of California, San Diego

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Guido Frank, Professor, University of California, San Diego
    ClinicalTrials.gov Identifier:
    NCT05834816
    Other Study ID Numbers:
    • 805807
    First Posted:
    Apr 28, 2023
    Last Update Posted:
    May 4, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 4, 2023